Pharmaceutical companies usually are involved in a lengthy process of getting their drug candidates to market through clinical trials. There is a fair amount of risk involved, should a study come back negative or a candidate not be approved. Conversely, if a drug gains FDA approval or passes a clinical trial, there can be big upside.
The White House has promised reforms in the health care sector, such as changing the bidding process for drugs and shortening the FDA approval process. It has yet to be seen how much headway they can actually make with these reforms.
Keep in mind that short sellers betting against big pharma are taking on an added risk. They have to pay out the ongoing high dividends on top of the cost of borrowing the shares.
The February 15 short interest data have been compared with the previous figures, and short interest in these selected pharmaceutical stocks increased.
Short interest in Pfizer Inc. (NYSE: PFE) increased to 64.13 million shares from the previous 56.96 million. Its shares were last seen at $36.80, within a 52-week trading range of $31.67 to $39.43.
The number of Merck & Co. Inc. (NYSE: MRK) shares short increased to 23.81 million from 23.49 million in the previous period. Its shares were trading at $54.72, in a 52-week range of $53.36 to $66.80.
Teva Pharmaceutical Industries Ltd.’s (NYSE: TEVA) short interest increased to 71.09 million from the previous level of 65.70 million. Shares were trading at $19.38, in a 52-week range of $10.85 to $35.64.
Bristol-Myers Squibb Co. (NYSE: BMY) short interest increased to 14.57 million shares from the previous reading of 12.40 million. Shares were trading at $67.84, within a 52-week range of $51.56 to $70.05.
The number of shares short in AbbVie Inc. (NYSE: ABBV) increased to 18.55 million, compared to the previous 17.47 million. The stock was trading at $118.26, in a 52-week range of $61.95 to $125.86.
Eli Lilly and Co.’s (NYSE: LLY) short interest increased to 11.03 million shares from the previous 11.57 million. The stock was trading at $78.70. The 52-week range is $73.69 to $89.09.
Travel Cards Are Getting Too Good To Ignore
Credit card companies are pulling out all the stops, with the issuers are offering insane travel rewards and perks.
We’re talking huge sign-up bonuses, points on every purchase, and benefits like lounge access, travel credits, and free hotel nights. For travelers, these rewards can add up to thousands of dollars in flights, upgrades, and luxury experiences every year.
It’s like getting paid to travel — and it’s available to qualified borrowers who know where to look.
We’ve rounded up some of the best travel credit cards on the market. Click here to see the list. Don’t miss these offers — they won’t be this good forever.
Thank you for reading! Have some feedback for us?
Contact the 24/7 Wall St. editorial team.
Latest from 24/7
